HPV Testing in the Evaluation of the Minimally Abnormal Papanicolaou Smear



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 1999 May 15;59(10):2794-2800.

  See related patient information handout on HPV testing, written by the authors of this article.

Minor cytologic abnormalities of the cervix, such as atypical squamous cells of undetermined significance (ASCUS), are vastly more common than high-grade squamous intraepithelial lesions or invasive cancer. Current guidelines for the management of ASCUS include repeating the Papanicolaou (Pap) smear at specific intervals, referring all patients for colposcopy or using an adjunctive test such as hybrid capture human papillomavirus (HPV) testing or cervicography. The usefulness of the Pap smear is limited by its considerable false-negative rate and its dependence on clinician and laboratory performance. Colposcopy is a highly sensitive procedure, but many patients with ASCUS have normal colposcopic findings. The hybrid capture test not only measures quantitative HPV load but also detects both oncogenic and nononcogenic HPV types, thereby increasing the probability that serious cervical disease is not missed. Hybrid capture sampling is simple to perform, and positive results are strongly associated with cervical dysplasia. HPV testing in women with ASCUS can be used as an adjunctive test to identify those with HPV-associated disease; it can also serve as a quality assurance measure. Together, repeat Pap smears and HPV testing should identify most patients with underlying cervical dysplasia. Combined testing may also minimize the number of unnecessary colposcopic examinations in women who have no disease.

Implementation of the Bethesda System has made the management of minimally abnormal Papanicolaou (Pap) smears more problematic because of the increased reporting of minor cytologic abnormalities, specifically atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intra-epithelial lesions (LSILs).1 Minor cytologic abnormalities are vastly more common than high-grade squamous intraepithelial lesions (HSILs) or invasive carcinoma. Determining optimal triage of these abnormalities can be difficult.

Whereas HSILs are significantly correlated with high-grade abnormalities or malignant histologic findings, minimally abnormal Pap smears reveal histologic findings ranging from normal to invasive.2 Patients with minor cytologic abnormalities frequently have normal colposcopic findings.3 Several studies, however, have emphasized that a minimally abnormal Pap smear may be the first indication of HSIL.4 One recent study5 looked at the relative contributions of cytologic diagnoses in 46,009 nonpregnant women to the subsequent histologic diagnosis of HSIL. The most common cytologic diagnosis immediately preceding the discovery of histologic HSIL was ASCUS (38.8 percent), followed by HSIL (31.4 percent), LSIL (20.1 percent) and atypical glandular cells (9.7 percent). This study showed that almost two thirds of histologic HSIL cases were preceded by a minimally abnormal Pap smear. Consequently, some experts advocate the use of colposcopy in all patients with ASCUS.4 Unfortunately, the results in many of these examinations are normal. In such instances, the Pap smear was overinterpreted, and the patient did not actually have malignant or premalignant disease.

Several algorithms for the management of the minimally abnormal Pap smear have been proposed, but they represent only preliminary attempts at defining the best triage plan.68 Currently, triage protocols include repeating the Pap smear at specific intervals (Figure 1),6,7,9 referring all patients initially for colposcopy or using an adjunctive test such as cervicography or human papillomavirus (HPV) testing.68 Until further trials have been completed, physicians need to decide how to manage the minimally abnormal Pap smear based on the best available evidence.

Pap Smear Showing ASCUS: Repeat Pap Smears

FIGURE 1.

Repeat smears in the management of the patient with a Papanicolaou (Pap) smear showing atypical squamous cells of undetermined significance (ASCUS). (SIL = squamous intraepithelial lesion)

Information from references 6,7 and 9.

View Large

Pap Smear Showing ASCUS: Repeat Pap Smears


FIGURE 1.

Repeat smears in the management of the patient with a Papanicolaou (Pap) smear showing atypical squamous cells of undetermined significance (ASCUS). (SIL = squamous intraepithelial lesion)

Information from references 6,7 and 9.

Pap Smear Showing ASCUS: Repeat Pap Smears


FIGURE 1.

Repeat smears in the management of the patient with a Papanicolaou (Pap) smear showing atypical squamous cells of undetermined significance (ASCUS). (SIL = squamous intraepithelial lesion)

Information from references 6,7 and 9.

Although the Pap smear has dramatically reduced the incidence of cervical cancer in screened populations, its considerable false-negative rate and relative insensitivity as a screening method continue to frustrate both clinicians and pathologists. Furthermore, despite attempts to improve the sensitivity of the Pap smear, many women are still not having the test as recommended. Improving the technology will not affect this situation.

Colposcopy is a highly sensitive method of detecting squamous intraepithelial lesions and invasion. However, the procedure is expensive and requires advanced training to perform. Most importantly, it is an excessive intervention that is not mandated for use in women who have minor cytologic abnormalities but are free of disease.

HPV testing has been proposed as an adjunctive test to improve the sensitivity and negative predictive value of the Pap smear. At a reduced cost, HPV testing could improve sensitivity with only modest changes in specificity.9 The ultimate usefulness of HPV testing will depend on the efficacy of the test itself as data from diverse populations are compared, the prevalence of HPV-associated disease in these populations is defined and the impact of the test in decreasing the mortality rate for cervical cancer is studied. At this time, no data are available to support the ability of HPV testing to reduce the incidence of cervical cancer.

Role of High- and Low-Risk HPV Types

Over the past decade, studies have attempted to define the relationship between HPV and lower genital tract neoplasia. Of the more than 70 HPV types that have been identified, about 30 infect the cervix. The HPV types most commonly detected in the cervix are listed in Table 1.9

TABLE 1

Selected Human Papillomavirus (HPV) Types According to Risk Status

Risk status HPV type number

High-risk or oncogenic HPV types

16, 18, 31, 33, 35, 45, 51, 52, 56, 58

Low-risk HPV types

6, 11, 42, 43 and 44


Information from Ferenczy A. Viral testing for genital human papillomavirus infections: recent progress and clinical potentials. Int J Gynecol Cancer 1995;5:321-8.

TABLE 1   Selected Human Papillomavirus (HPV) Types According to Risk Status

View Table

TABLE 1

Selected Human Papillomavirus (HPV) Types According to Risk Status

Risk status HPV type number

High-risk or oncogenic HPV types

16, 18, 31, 33, 35, 45, 51, 52, 56, 58

Low-risk HPV types

6, 11, 42, 43 and 44


Information from Ferenczy A. Viral testing for genital human papillomavirus infections: recent progress and clinical potentials. Int J Gynecol Cancer 1995;5:321-8.

Current data support the hypothesis that the spectrum of cervical disease referred to as cervical intraepithelial neoplasia (CIN) consists of histologically distinct entities: low-grade CIN and high-grade CIN.10 High-grade CINs are associated with the same HPV types, and most of these CINs contain oncogenic HPV types. Women with oncogenic HPV types are at greatest risk of developing HSIL and cervical neoplasia.11 High levels of oncogenic HPV types also appear to be predictive of the presence of persistent or progressive CIN.12

Fewer than 30 percent of low-grade CINs contain oncogenic HPV types. Thus, the likelihood of invasion is low. Low-grade CINs that lack oncogenic HPV types are also unlikely to progress to high-grade CINs.10 In one study, HPV was detected in 79.3 percent of specimens from women with definite cervical disease, 23.7 percent of specimens from women with borderline atypia and 6.4 percent of specimens from normal women.13 Low-risk HPV types were absent in all cancers. The presence of oncogenic HPV types conferred odds ratios ranging from 65.1 to 235.7 for the presence of a high-grade lesion and 31.1 to 296.1 for an invasive cancer.13

The presence of HPV in women with normal Pap smears has prognostic significance. In one study, about 28 percent of HPV-positive women developed histologically confirmed CIN.14 Furthermore, more than 50 percent of the women who developed CIN grade 2 or 3 did so within 24 months of the initial positive HPV test, whether or not they developed CIN grade 1 as the initial step.14 In most of these women, CIN grade 2 or 3 was found within six months after the initial detection of oncogenic HPV types.15 The negative predictive value (i.e., the likelihood that a woman without HPV infection does not have high-grade CIN) is greater than 97 percent.16

HPV Testing

The association of oncogenic HPV types, high-grade CIN and invasive cancer has been an impetus for feasibility studies on the use of HPV testing in clinical practice. Until recently, an acceptably sensitive and easily performed HPV test was not available. By improving the sensitivity of the Pap smear, HPV testing could be used to identify patients who have serious disease despite negative cytologic studies.17 On the other hand, overzealous and irrational use of HPV testing could result in overmanagement and overtreatment of patients with low-risk, transient HPV-associated disease.

The concept of HPV testing is not new but represents evolving technology. Positive results are strongly associated with the presence of concurrent CIN.16,18 The Hybrid Capture HPV DNA Assay (Digene Corporation, Silver Spring, Md.) currently labeled by the U.S. Food and Drug Administration has the capability of measuring quantitative viral load, thereby increasing test specificity.19 This test identifies 14 clinically significant HPV types. It is easier and more economical to use than older HPV tests (e.g., ViraPap, Digene Corporation), and it provides more clinically useful information about the presence or absence of HPV.20 The current cost of the hybrid capture test ranges from $35 to $55.

The hybrid capture kit consists of a Dacron-tipped swab and a transport tube packaged in a cardboard container supplied by the manufacturer. The sample is collected from the endocervix and ectocervix with the swab, which is then placed in the proprietary transport medium. The specimen is denatured in the laboratory, and the liberated single-stranded DNA is hybridized in a solution with an RNA probe mix consisting of low- and high-risk HPV types.

The resulting bound DNA-RNA “hybrids” are reacted with an antibody directed against the hybrids. The unreacted material is removed, and a chemiluminescent substrate, which binds to the antibody, is added. Because the amount of light produced by hybrid capture is proportional to the amount of DNA in each specimen, the amount of emitted light correlates with the viral load.9 The higher the number of light units, the greater the amount of HPV DNA in the specimen.19 High signal output correlates with higher grade histologic severity. This study found that no high-grade lesions were missed when a 16-probe panel was used.

Most recent studies have evaluated hybrid capture HPV as an intermediate screening test in women with abnormal cytologic findings rather than as a primary screening test. A highly significant correlation appears to exist between a positive hybrid capture test and the finding of CIN or invasion on histologic examination.18 One study of 311 women with a cytologic diagnosis of LSIL, HSIL or cancer found that when used alone, the hybrid capture test had a sensitivity of 74 percent for the detection of CIN; sensitivity increased to 91 percent when a positive hybrid capture test was coupled with an abnormal Pap smear (LSIL, HSIL or cancer).21 In 44 women with ASCUS, six of the 10 women with high-grade lesions were identified by hybrid capture HPV testing. In 96 women with LSIL on Pap smear, 29 of the 37 high-grade lesions were detected by the hybrid capture HPV test. This 60 to 76 percent sensitivity is somewhat higher than the 58 percent sensitivity previously reported for repeating the Pap smear alone.22

A limitation of the study was that hybrid capture HPV testing failed to identify four of nine significant high-grade lesions, including one cervical cancer.21 Patients with cervical cancer may have poor recovery of HPV because of tumor necrosis and bleeding. This problem needs to be assessed in future studies.

In a study of 967 women who underwent routine cytologic screening, 38 women were identified as having histologic CIN grade 2 or 3.23 Repeat Pap smears, cervicography and hybrid capture testing at the time of biopsy identified 29 percent, 45 percent and 50 percent, respectively, of the women who had CIN grade 2 or 3. The combination of HPV testing and cytologic screening had a 58 percent sensitivity for CIN grade 2 or 3. In 27 women, CIN 2 or 3 was not detected by the Pap smear alone. Detection of high-risk HPV types by hybrid capture testing proved to be the most valuable technique for identifying CIN 2 or 3. Augmentation of cytolologic testing with the hybrid capture HPV test was more cost-effective than cervicography in identifying CIN grade 2 or 3.

Management of the Minimally Abnormal Pap Smear

Interim guidelines for the management of abnormal cytologic findings in the cervix were developed at a workshop sponsored by the National Cancer Institute and published in 1994.6 These guidelines suggest that both HPV testing and cervicography can be used as adjunctive tests to help identify patients at low or high risk of developing CIN and cancer. The American Society of Colposcopy and Cervical Pathology subsequently issued guidelines for the management of ASCUS.7 The high prevalence of HPV in young sexually active women has focused attention on the applicability of HPV testing as a general screening tool. It appears that in certain situations, HPV testing may help guide management decisions.9

Women less than 30 years old display a high rate of HPV positivity with normal cytologic findings. As many as 20 percent of women between the ages of 20 and 25 years are positive for HPV; after the age of 30 years, this figure drops to less than 5 percent.24 In one study, the HPV status of women undergoing hysterectomy, conization or loop excision biopsy was correlated with the histologic findings.25 The cervixes of eight of 10 women over the age of 40 years who had CIN or cancer were positive for high-risk HPV types. The authors of the study noted that the higher incidence of HPV in the histologically abnormal cervixes of high-risk women and the extremely low rate of HPV in routine hysterectomy specimens indicated that high-risk HPV types are uncommon in older women in the absence of morphologic abnormalities. They concluded that the finding of oncogenic HPV types in older women is clinically significant.

Another study found that compared with HPV-negative women, HPV-positive women are more likely to have histologic CIN even if they have negative cytologic findings or ASCUS.26 HPV-negative women are much more likely to have no visible lesion on colposcopy or to have normal histologic findings on biopsy samples obtained from areas that appear abnormal. The authors suggested that combined use of hybrid capture HPV testing and a repeat Pap smear would detect nearly all women with HSIL, thereby limiting unnecessary colposcopic examinations in women without disease.26 In this study, the test combination correctly identified 90 percent of women with histologic CIN. If the women in the study tested negative for oncogenic HPV twice, the negative predictive value approximated 100 percent.

The results of another study showed that the use of a repeat Pap smear combined with hybrid capture HPV testing correctly identified 96 percent of women with high-grade CIN.27 The authors suggested that this combination protocol could be especially effective when colposcopy resources are scarce, the prevalence of HSIL is low or patients wish to avoid colposcopy.

The combined negative predictive value of hybrid capture HPV testing and a repeat Pap smear would mean that a woman is at extremely low risk of developing cervical neoplasia. Most women who are HPV negative for a considerable period do not develop significant cervical disease.28 Thus, the combined negative predictive value of the two tests can reassure the physician and patient that a significant cellular abnormality has not been missed and may allow Pap smears to be performed at less frequent intervals.29

HPV testing could also be used as a measure of quality assurance in laboratories with higher than acceptable ASCUS rates.9 If a laboratory is reporting ASCUS rates in greater than 5 percent of women, the majority of these patients will have normal colposcopic findings. The higher the ASCUS rate, the greater the probability that the Pap smear is being misread. Thus, hybrid capture HPV testing could limit unnecessary colposcopic examinations in women who do not have disease.9

A suggested algorithm for triage of the ASCUS smear using hybrid capture HPV testing is presented in Figure 2.6,7,9 Until prospective trials determine the most appropriate management strategy for the minimally abnormal Pap smear, HPV testing should be viewed as an adjunctive test. Its purpose is to increase the identification of patients who have significant HPV-associated disease and to avoid unnecessary colposcopic examinations in patients who have normal morphology and whose Pap smears are overread or misclassified.

PAP Smear Showing ASCUS: HPV Testing

FIGURE 2.

Hybrid capture human papillomavirus (HPV) DNA testing in the management of the patient with a Papanicolaou smear showing atypical squamous cells of undetermined significance (ASCUS). (SIL = squamous intraepithelial lesion)

Information from references 6,7 and 9.

View Large

PAP Smear Showing ASCUS: HPV Testing


FIGURE 2.

Hybrid capture human papillomavirus (HPV) DNA testing in the management of the patient with a Papanicolaou smear showing atypical squamous cells of undetermined significance (ASCUS). (SIL = squamous intraepithelial lesion)

Information from references 6,7 and 9.

PAP Smear Showing ASCUS: HPV Testing


FIGURE 2.

Hybrid capture human papillomavirus (HPV) DNA testing in the management of the patient with a Papanicolaou smear showing atypical squamous cells of undetermined significance (ASCUS). (SIL = squamous intraepithelial lesion)

Information from references 6,7 and 9.

The Authors

BARBARA S. APGAR, M.D., M.S., is clinical associate professor in the Department of Family Medicine at the University of Michigan Medical School, Ann Arbor. Dr. Apgar received a medical degree from Texas Tech University School of Medicine, Lubbock, where she also completed a residency in family practice. In addition, she completed a master's degree program at the University of Michigan and a faculty development fellowship at Michigan State University College of Human Medicine, East Lansing.

GREGORY BROTZMAN, M.D., is associate professor in the Department of Family and Community Medicine at the Medical College of Wisconsin, Milwaukee. In addition, he is a full-time faculty member at Columbia Family Practice Residency Program, Milwaukee, and maintains an active practice in colposcopy. Dr. Brotzman graduated from Southern Illinois University School of Medicine, Springfield, and completed a residency in family practice at that institution.

Address correspondence to Barbara S. Apgar, M.D., M.S., Chelsea Family Practice Center, 14700 E. Old U.S. Highway 12, Chelsea, MI 48118. Reprints are not available from the authors.

REFERENCES

1. The 1988 Bethesda System for reporting cervical/ vaginal cytological diagnoses. JAMA. 1989;262:931–4.

2. Montz FJ, Monk BJ, Fowler JM, Nguyen L. Natural history of the minimally abnormal Papanicolaou smear. Obstet Gynecol. 1992;80(3 pt 1):385–8.

3. Gonzalez D, Hernandez E, Anderson L, Heller P, Atkinson BF. Clinical significance of a cervical cytologic diagnosis of atypical squamous cells of undetermined significance. Favoring a reactive process or low grade squamous intraepithelial lesion. J Reprod Med. 1996;41:719–23.

4. Reiter RC. Management of initial atypical cervical cytology: a randomized, prospective study. Obstet Gynecol. 1986;68:237–40.

5. Kinney WK, Manos MM, Hurley LB, Ransley JE. Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol. 1998;91:973–6.

6. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. JAMA. 1994;271:1866–9.

7. ASCCP Practice Guideline. Management guidelines for follow-up of atypical squamous cells of undetermined significance (ASCUS). Colposcopist. 1996;27:1–9.

8. Brotzman GL, Julian TM. The minimally abnormal Papanicolaou smear. Am Fam Physician. 1996;53:1154–64.

9. Ferenczy A. Viral testing for genital human papillo-mavirus infections: recent progress and clinical potentials. Int J Gynecol Cancer. 1995;5:321–8.

10. Lungu O, Sun XW, Felix J, Richart RM, Silverstein S, Wright TC Jr. Relationship of human papillomavirus type to grade of cervical intraepithelial neoplasia. JAMA. 1992;267:2493–6.

11. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993;85:958–64.

12. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995;87:1365–71.

13. Lorincz AT, Reid R, Jenson B, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infections of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 1992;79:328–37.

14. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327:1272–8.

15. Kiviat NB, Koutsky LA. Do our current cervical cancer control strategies still make sense? J Natl Cancer Inst. 1996;88:317–8.

16. Kjellberg L, Wiklund F, Sjoberg I, Wadell G, Angstrom T, Dillner J, et al. A population-based study of human papillomavirus deoxyribonucleic acid testing for predicting cervical intraepithelial neoplasia. Am J Obstet Gynecol. 1998;179(6 pt 1):1497–502.

17. Schiffman MH. Latest HPV findings: some clinical implications. Contemp Obstet Gynecol. 1993;38:27–41.

18. Sun XW, Ferenczy A, Johnson D, Koulos JP, Lungu O, Richart RM, et al. Evaluation of the Hybrid Capture human papillomavirus deoxyribonucleic acid detection test. Am J Obstet Gynecol. 1995;173:1432–7.

19. Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 1995;172:946–54.

20. Schiffman MH, Kiviat NB, Burk RD, Shah KV, Daniel RW, Lewis R, et al. Accuracy and interlaboratory reliability of human papillomavirus DNA testing by hybrid capture. J Clin Microbiol. 1995;33:545–50.

21. Hatch KD, Schneider A, Abdel-Nour MW. An evaluation of human papillomavirus testing for intermediate- and high-risk types as triage before colposcopy. Am J Obstet Gynecol. 1995;172(4 pt 1):1150–7.

22. Spitzer M, Krumholz BA, Chernys AE, Seltzer V, Lightman AR. Comparative utility of repeat Papanicolaou smears, cervicography, and colposcopy in the evaluation of atypical Papanicolaou smears. Obstet Gynecol. 1987;69:731–5.

23. Schneider A, Zahm DM, Kirchmayr R, Schneider VL. Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cevicography, and human papillomavirus detection. Am J Obstet Gynecol. 1996;174:1534–41.

24. Melkert PW, Hopman E, van den Brule AJ, Risse EK, van Diest PJ, Bleker OP, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer. 1993;53:919–23.

25. Shen LH, Rushing L, McLachlin CM, Sheets EE, Crum CP. Prevalence and histologic significance of cervical human papillomavirus DNA detected in women at low and high risk for cervical neoplasia. Obstet Gynecol. 1995;86(4 pt 1):499–503.

26. Cox JT, Schiffman MH, Winzelberg AJ, Patterson JM. An evaluation of human papillomavirus testing as part of referral to colposcopy clinics. Obstet Gynecol. 1992;80(3 pt 1):389–95.

27. Wright TC, Sun XW, Koulos J. Comparison of management algorithms for the evaluation of women with low-grade cytologic abnormalities. Obstet Gynecol. 1995;85:202–10.

28. Moscicki AB, Palefsky J, Smith G, Siboshski S, Schoolnik G. Variability of human papillomavirus DNA testing in a longitudinal cohort of young women. Obstet Gynecol. 1993;82(4 pt 1):578–85.

29. Remmink A, Walboomers JM, Helmerhorst T, Voorhorst F, Rozendaal L, Risse E, et al. HPV in follow-up of patients with cytomorphologically abnormal cervical smears: a prospective nonintervention study. Int J Cancer. 1995;61:306–11.



Copyright © 1999 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article